Clinical trial · Interventional
The Effect of Intravenous Lidocaine on THBS2 and Angiogenic Factors Expression in Women Undergoing Cervical Cancer Surgery
Effects of Intravenous Lidocaine on Serum THBS2, MMPS and VEGF-C in Patients Undergoing Radical Hyterectomy Surgery After General Anesthesia
NCT05560035CI-TRIAL-00061124unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate the efficacy of intravenous lidocaine on THBS2, MMPs and VEGF-C in serum in cervical cancer patients undergoing radical hysterectomy under general anesthesia.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lidocaine | Drug | — | UNRESOLVED |
| Normal saline (NS) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Lidocaine
- description
- Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the first hour, 1.5 mg/kg for the second hour, 0.7 mg/kg for the next 22h.
- interventionNames
- Drug: Lidocaine
- type
- PLACEBO_COMPARATOR
- label
- Normal saline
- description
- Normal saline administered as a bolus and an infusion with identical volume and rate changes as the treatment group.
- interventionNames
- Other: Normal saline (NS)
Primary outcomes (4)
- measure
- Changes from Baseline THBS2 before anaesthetic induction and 48 hours after surgery
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients were scheduled by following cervical cancer surgery under general anesthesia * Aged 18-65 years * ASA physical status Ⅱ-Ⅲ Exclusion Criteria: * Severe heart, pulmonary, hepatic and renal insufficiency * History of neurological diseases * Autoimmune disorders * Antiarrhythmic drugs (amiodarone, verapamil, propafenone) * Patients' decision to withdraw anytime from the study, and refusal to participate before surgery and at postoperative follow-up * Allergy to one of the used medications * Psychiatric illness, psychological disorder, and drug or alcohol abuse * Unwillingness to comply with the protocol or procedures * Preoperative treatment of chemotherapy, radiation, NSAID and hormonal therapy * History of anesthesia and surgery in two weeks * Coexisting other cancers and intraoperative presence of liver metastasis * Perioperative treatment of blood transfusion
References
Publications (0)
Data not yet available
No reference posted for this study.